Plasmatic HGF level was increased in GC patients compared to HC patients (1407 ± 126 pg/mL vs. 658.6 ± 153 pg/mL, p = 0.031; Supplementary Figure S1A) and was associated with a more advanced disease phenotype since metastatic patients exhibited higher levels of plasmatic HGF than patients with localized disease (1726 ± 136.3 pg/mL vs. 1010 ± 152.9 pg/mL, p = 0.0047; Supplementary Figure S1B), as previously reported [17]. The gene discussed is HGF; the disease is gastric cancer.